Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RIVe-CLL/SLL)

NCT03639324 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT03639324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03639324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RIVe-CLL/SLL)
Lead sponsor
Virginia Commonwealth University
Phase
Phase 1
Overall status
Withdrawn
Start date
October 2, 2020
Completion date
October 18, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, cll, refractory chronic lymphocytic leukemia, refractory small lymphocytic lymphoma, relapsed chronic lymphocytic leukemia, relapsed cll, relapsed small lymphocytic lymphoma, sll, small lymphocytic lymphoma